Illumina heads into the first week of September with a story that has shifted materially since last week's note — short sellers are now pulling back, but the director who sold aggressively into late-August strength is still at it.
The most notable development is Keith Meister's continued selling. The Corvex-linked director added another large tranche to his exit program, selling roughly 194,000 additional shares across September 3 and 4, collecting approximately $42 million at prices between $215 and $222. Combined with the roughly $54 million raised in the final days of August, Meister has now cleared close to $300 million from his ILMN position in under two weeks — none of it under a pre-arranged 10b5-1 plan. The 90-day insider net across the register runs to -1.4 million shares and nearly -$307 million in value. That is a substantial, sustained, discretionary exit by a board insider, and the magnitude puts it in a different category from routine portfolio management. The Corvex institutional stake, last reported at 1.87% of shares in June, has likely moved materially lower since then.
Short positioning is telling a less aggressive story than it was last week, and that contrast matters. SI has eased to 6.4% of the free float — down nearly 5% on the week — reversing part of the sharp build that ran from late July through late August. That build peaked around 6.8% of float on August 27; the unwinding coincides almost exactly with Meister's sales, suggesting some short sellers may have covered into the same window of weakness. The borrow market remains loose: availability is at 491%, well above the 52-week floor of 418% hit on August 27, and cost to borrow has drifted down to around 0.46%. There is no squeeze pressure here. The ORTEX short score has also eased gradually from 53.2 on August 27 to 51.2, consistent with a market that is trimming rather than adding bearish bets.
The Street's posture is broadly constructive but fractured by valuation. Following the July 30 earnings print — which pushed the stock up roughly 5% on the day — most covering analysts raised their targets. The bulls at Argus (this week lifting to $235), Piper Sandler ($225), Guggenheim ($226), and RBC ($230) see room for further gains. JPMorgan, also positive, moved its target to $230. The holdouts are harder to dismiss: Citigroup maintains a Sell with a $113 target, and Barclays sits at Underweight with $160. The consensus mean of around $200 now sits below the current price of $218, which means the average analyst view already implies modest downside from here. The bull case rests on Illumina's NGS platform dominance and oncology market momentum; the bear case centres on China exposure — the company remains on the unreliable entity list with no clear resolution — and intensifying competition in next-generation sequencing. The P/E multiple has re-rated sharply over the past month, expanding by roughly 4.4 turns to nearly 39x, and price-to-book has risen by 1.2 turns over the same period. That kind of multiple expansion ahead of the next earnings print on October 30 puts a higher bar on execution.
Institutional ownership adds one more layer worth noting. Capital World Investors trimmed its stake from 13.2% to 10.3% in a May filing, while FMR added roughly 2.5 million shares as of July. Wellington Management also added meaningfully — over 1.1 million shares — in the same period. The divergence between growth-oriented buyers and sellers trimming from elevated weights has been a consistent feature of ILMN's register for several months. Capital Research (the active arm of American Funds, distinct from Capital World) holds 10.4% and added 1 million shares in July, making it one of the clearest conviction holders at current levels.
Among correlated peers, MRVI fell nearly 5% on the week and PACB dropped 3.6%, while RVTY and TEM held broadly flat. ILMN's 1.2% weekly gain is relative outperformance within the group, which makes the continued insider selling into that relative strength all the more striking. The next scheduled catalyst is the Q3 earnings print on October 30 — the question heading into that date is whether Meister's exit accelerates further, and whether China revenue trends show any signs of stabilisation that could justify the multiple expansion already priced in.
See the live data behind this article on ORTEX.
Open ILMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
